Critical Reviews in Oncology / Hematology
Volume 79, Issue 2 , Pages 196-204, August 2011

Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals

  • P. Barthélémy

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • D. Heitz

      Affiliations

    • Unité Pilote d’Oncogériatrie, Hôpitaux Universitaires de Strasbourg and Centre Paul Strauss, Strasbourg, France
  • ,
  • C. Mathelin

      Affiliations

    • Pôle de Gynécologie – Obstétrique, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • H. Polesi

      Affiliations

    • Observatoire Régional de la Santé d’Alsace, Strasbourg, France
  • ,
  • I. Asmane

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • V. Litique

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • L. Rob

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • J.-P. Bergerat

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
  • ,
  • J.-E. Kurtz

      Affiliations

    • Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France
    • Unité Pilote d’Oncogériatrie, Hôpitaux Universitaires de Strasbourg and Centre Paul Strauss, Strasbourg, France
    • Corresponding Author InformationCorresponding author at: Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, France. Tel.: +33 3 88 12 84 36; fax: +33 3 88 12 76 81.

Accepted 25 June 2010. published online 26 July 2010.

Abstract 

Purpose of the study

Elderly breast cancer (EBC) patients are often denied adjuvant chemotherapy because of age. Breast cancer is among the most frequent cancer in Western Countries and recent data suggest that adjuvant chemotherapy could be active in selected elderly patients. We investigated the impact of age and comprehensive geriatric assessment (CGA) among other variables taken into account in tumor boards to recommend adjuvant chemotherapy in EBC patients.

Method(s)

We retrospectively reviewed breast cancer tumor board records of all consecutive EBC patients (over 70 years old) discussed from July 2006 to July 2009 in our institution. The recorded variables included age, comorbidities, tumor stage, grade, ER/PR and HER2 status, treatment characteristics and CGA conclusions. Agreement with breast cancer treatment guidelines was verified. Reasons for deviations were recorded.

Result(s)

A total of 192 early EBC patients files (mean age 76.7 years, range 70–98) were analyzed. Elderly patients were less likely to receive adjuvant chemotherapy even when deemed appropriate by guidelines (p<.001). Out of 118 patients with ≥1 risk factors (pT2–4, N+, RH−, SBR III), 70 were proposed adjuvant chemotherapy. In multivariate analysis, age >80 years, but not CGA result, was an independent variable associated with a decreased likelihood to receiving adjuvant chemotherapy. Moreover, 93 patients (48.4%) underwent CGA, of whom no Balducci's class III patient received adjuvant chemotherapy. An appropriate treatment was administered in only 69% and 42% of Balducci's class I and II patients, respectively.

Conclusion(s)

Our results suggest that age remains an independent variable associated with a decreased use of adjuvant chemotherapy. However, in our series systemic adjuvant chemotherapy was probably underused in “fit” patients. Further efforts are needed to better integrate CGA into tumor boards proposals for early EBC patients.

Keywords: Breast cancer, Elderly, Adjuvant chemotherapy, Geriatric assessment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(10)00148-4

doi:10.1016/j.critrevonc.2010.06.005

Critical Reviews in Oncology / Hematology
Volume 79, Issue 2 , Pages 196-204, August 2011